DAPA-PD, the phase 2 clinical trial of dapansutrile, is now underway

We are excited to announce that the first participant on the Cure Parkinson’s and Van Andel Institute co-funded trial of dapansutrile, an anti-inflammatory drug, has now received either the treatment or placebo, marking the beginning of the trial. What is DAPA-PD? Dapansutrile for Parkinson’s (DAPA-PD)…


News Research news

International Women’s Day 2026: The importance of investigating sex and gender in Parkinson’s research

Despite growing evidence that sex and gender play a meaningful role in how Parkinson’s is experienced, diagnosed, and treated, this is not consistently reflected in clinical studies or in our understanding of the condition. This International Women’s Day, we invite both researchers and the Parkinson’s…


Nominations for Cure Parkinson’s Fundraiser of the Year are open!

Nominations for Cure Parkinson’s 2025 Fundraiser of the Year award are now open! Each year, we award a ‘ Fundraiser of the Year’ to a supporter who has gone above and beyond to raise vital funds and awareness for our research. Last year’s winners were…


News Research news

Cure Parkinson’s iLCT Pipeline Research Acceleration Programme opens new funding call

Cure Parkinson’s is excited to announce the opening of the iLCT Pipeline Research Acceleration Programme for February 2026. We are welcoming applications to investigate secukinumab in an alpha-synuclein model of Parkinson’s. What is the iLCT Pipeline Research Acceleration Programme? Each year, a committee of over…


News Fundraising news

Cure Parkinson’s Fundraising Heroes: January 2026

Our supporters ran, rowed, and rounded up a year of fundraising activities for us. 52 miles in a month At the end of 2025, supporters Julie and Sophie (and their dogs) decided to run 52 miles in a month to raise funds and awareness for…